Artivion, Inc.
NYSE:AORTMedical - Devices
-$0.11 today
- Market cap
- $904.56M
- Beta
- 1.26
- P/E (TTM)
- 86.7
- EPS (TTM)
- $0.24
Volume 0.91M
Average 0.64M
AORT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Artivion, Inc.NYSE: AORT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $1.42M, compared with -$505K a year earlier. Trailing-twelve-month net income was $11.69M.
Context
- Net income amounted to 2.2% of revenue in FY2025, down 1.2 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of $18.63M (+90.7%) for the fiscal year ending Dec 2026, a slowdown from the +173.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.42M-41.6% QoQ
- Last fiscal yearDec 2025
- $9.77M+173.1% YoY
- LTMMar 2026
- $11.69M+154.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +380.6% | -90.9% | -471.5 pp |
| 1 year | +173.1% | +90.7% | -82.4 pp |
| 3-year CAGR | — | +20.1% | — |
| 5-year CAGR | +50.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 9.77M USD
- Year-over-year change
- +173.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.77M | +173.1% |
| FY2024 | 2024-12-31 | (13.36M) | +56.5% |
| FY2023 | 2023-12-31 | (30.69M) | -59.9% |
| FY2022 | 2022-12-31 | (19.19M) | -29.4% |
| FY2021 | 2021-12-31 | (14.83M) | — |
Net Income vs competitors
How AORT compares with its peers on the latest reported figures
- AORT's LTM Mar 2026 net income of $11.69M is the 10th largest of the 11 companies compared; the peer median is $33.71M.
- Its year-over-year change of +154.6% is the 2nd highest of 11, against a peer median of +44.0%.
- Net income amounts to 2.5% of revenue for AORT, versus a peer median of 7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $377.18M | +32.8% | +32.9% | — | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $186.34M | -23.1% | -4.6% | 2.9% |
| LTM Jun 2026 | $135.04M | +154.2% | — | 15.0% | |
| LTM Jun 2026 | $130.38M | +57.1% | +27.7% | 8.8% | |
| LTM Jul 2026 | $128.4M | +55.3% | +15.7% | 7.0% | |
| LTM Mar 2026 | $102.47M | +13.6% | +3.1% | 31.8% | |
| LTM Jun 2026 | $50.6M | +413.3% | — | 3.2% | |
| LTM Sep 2026 | $23.41M | -92.4% | +3.3% | 0.8% | |
| LTM Jun 2026 | $16.82M | +111.9% | +18.9% | 3.7% | |
| LTM Mar 2026 | $11.69M | +154.6% | — | 2.5% | |
| LTM Mar 2026 | $10.03M | -33.1% | +55.7% | 20.7% | |
| Peer median (excluding AORT) | $33.71M | +44.0% | +17.3% | 7.0% | |
Competitors are the stored peer set for AORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.83M) | (19.19M) | (30.69M) | (13.36M) | 9.77M |
| Depreciation & Amortization | 23.98M | 22.44M | 23.08M | 24.21M | 22.46M |
| Deferred Income Tax | (4.47M) | (1.72M) | (1.39M) | (1.51M) | 37K |
| Stock-Based Compensation | 10.71M | 12.34M | 14.42M | 14.24M | 24.39M |
| Change in Working Capital | (33.23M) | (25.94M) | (16.19M) | (17.24M) | (22.16M) |
| Accounts Receivables | (11.56M) | (13.34M) | (4.05M) | (15.4M) | (7.27M) |
| Inventory | (18.38M) | (8.4M) | (14.36M) | (6.14M) | (15.28M) |
| Accounts Payables | (1.89M) | (1.96M) | 1.68M | 9.5M | 2.18M |
| Other Working Capital | (1.4M) | (2.23M) | 535K | (5.21M) | (1.8M) |
| Other Non-Cash Items | 15.26M | 6.91M | 29.6M | 15.9M | 3.64M |
| Operating Cash Flow | (2.59M) | (5.15M) | 18.83M | 22.24M | 38.13M |
| Capital Expenditures | (13.09M) | (10.72M) | (7.43M) | (11.19M) | (39.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 19M | 0 | 0 | 0 | 0 |
| Other Investing Activities | (249K) | 0 | 6.93M | (17M) | (3M) |
| Investing Cash Flow | 5.66M | (10.72M) | (502K) | (28.19M) | (42.04M) |
| Debt Repayment | (3.09M) | (2.75M) | (2.77M) | (358K) | (2.46M) |
| Common Stock Issued | 0 | 0 | 0 | 5.73M | 13.07M |
| Common Stock Repurchased | (1.91M) | (1.8M) | (559K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.22M) | 2.91M | 4.2M | (3.17M) | 2.42M |
| Financing Cash Flow | (12.22M) | (1.64M) | 865K | 2.2M | 13.03M |
| Effect of Forex Changes | 2.2M | 1.85M | 401K | (1.73M) | 2.32M |
| Net Change in Cash | (6.95M) | (15.66M) | 19.59M | (5.48M) | 11.45M |
| Free Cash Flow | (15.68M) | (15.87M) | 11.4M | 11.05M | (911K) |
Artivion, Inc.
NYSE:AORT
Intrinsic Alpha fair value
Locked
Current Price
$18.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.